NewLimit has announced a $435 million Series C led by Founders Fund, alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others. The raise will fund the company’s first aging reprogramming medicine into human clinical trials next year, a timeline accelerated by the breakthrough discovery of a prototype medicine that reverses cell age in old human liver cells.
NewLimit’s medicines are designed to restore youthful function in old cells through epigenetic reprogramming — a field that has challenged prior scientific dogma by demonstrating that aging is plastic at the cellular level. The company’s early work developed the artificial intelligence and genomics technology necessary to discover age reprogramming medicines, which have been deployed across therapeutic programs spanning metabolic, vascular, and immune health. The lead program, a liver reprogramming therapy, allows livers to heal faster after injury, avoid damage from dietary challenges, and accelerate recovery from alcohol consumption. The upcoming human trial will reveal for the first time how liver age reprogramming translates into clinical outcomes in people.
Founded in 2021 by Coinbase CEO and co-founder Brian Armstrong, former GV partner and bioengineer Blake Byers, and computational biologist Jacob Kimmel — who serves as CEO and President — NewLimit originally believed it would take more than a decade to bring one of its products into human trials. Recent scientific breakthroughs have compressed that timeline dramatically. Over the coming years, the company plans to add new therapeutic programs and build a diverse portfolio of aging therapies across multiple clinical indications, with the long-term ambition of treating aging itself as a condition that can be meaningfully reversed.
KEY QUOTES:
“We founded NewLimit to create medicines that treat aging and add healthy years to each of our lives. We initially believed it would take more than a decade to bring one of these products into human trials. Based on our recent scientific results, we’ve accelerated our timelines and plan to initiate our first human trial next year. In the success case, we believe inventing medicines for aging is one of the few projects that can benefit humanity for centuries to come.”
Jacob C. Kimmel, CEO and President, NewLimit
